U.S. economy added 379,000 jobs in February

The unemployment rate fell to 6.2%

Tetra Bio-Pharma Inc. (TBPMF)

Other OTC - Other OTC Delayed Price. Currency in USD

Add to watchlist

0.1230-0.0139 (-10.15%)

At close: 3:54PM EST

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Neutralpattern detected

View all chart patterns

Performance Outlook

Previous Close	0.1369
Open	0.1470
Bid	0.0000 x 0
Ask	0.0000 x 0
Day's Range	0.1224 - 0.1470
52 Week Range	0.0940 - 0.3100
Volume	660,275
Avg. Volume	439,933

Market Cap	43.323M
Beta (5Y Monthly)	1.93
PE Ratio (TTM)	N/A
EPS (TTM)	-0.0290
Earnings Date	N/A
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	N/A

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

N/A

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

News

Press Releases

Research Reports

ACCESSWIRE
Tetra Bio-Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
OTTAWA, ON / ACCESSWIRE / March 3, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announces that CEO Dr.
- Gentherm to Participate in Virtual Baird 2021 Vehicle Technology & Mobility Conference
  GlobeNewswire
- Mastercard to Participate in Upcoming Investor Conferences
  Business Wire
CNW Group
Tetra Bio-Pharma Announces Closing of Bought Deal Offering
/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/OTTAWA, ON, March 2, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development, is pleased to announce it has closed its previously announced bought-deal public offering of units (the "Units") of the Company.
- Nexus Real Estate Investment Trust Announces Closing of $34.9 Million Bought Deal Equity Offering
  GlobeNewswire
- International Consolidated Uranium Closes C$6 Million “Bought Deal” Private Placement of Units
  GlobeNewswire
ACCESSWIRE
Tetra Bio-Pharma To Monetize Its Dronabinol And Botanical Product Portfolios
Company signs LOI for Nordics and GermanyOTTAWA, ON / ACCESSWIRE / February 25, 2021 /Tetra Bio-Pharma Inc. ("Tetra" or the "Company")(TSX:TBP)(OTCQB:TBPMF), a biopharmaceutical pioneer in immunomodulator drug discovery and development announced the signing of a Letter of Intent with DanCann Pharma A/S (SS: DANCAN) for the exclusive distribution of Reduvo™ Adversa® and QIXLEEF™ in Denmark, Norway, Sweden, Finland, and Germany.